Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these…
With a flight to cash hardly workable for most investors, and Treasury bonds seemingly very rich, quality low-volatility dividend stocks make the most sense in for uncertain times.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Bats Global Markets, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer and SolarCity.
Eli Lilly is set to release its first-quarter earnings report before the markets open on Tuesday.
Chris Lange Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes anytime…
In a new research report, Credit Suisse highlighted some companies on its U.S. Focus List that stand to have the most potential price return.
These four solid companies to buy and hold all can do well, and even if the market sells off, the demand for their products and services will not. Plus, they all offer…
24/7 Wall St. has identified seven companies that could easily reach the $100 billion mark to become the next mega-cap stocks.
March 17, 2016: Here are four stocks trading with heavy volume among 60 equities making new 52-week lows in Thursday’s session. Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped another 11.4% on Thursday…
March 15, 2016: Here are four stocks trading with heavy volume among 33 equities making new 52-week lows in Tuesday’s session. Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped by more than 51%…
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
With investors looking for safety and dividends for total return, the big pharmaceutical stocks are just the ticket, and these four are outstanding.
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political…
